Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 36(2023), 5 vom: 03. Okt., Seite 545-546 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pérez Catalán, I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7R9A5P7H32 |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/028.2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358591236 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358591236 | ||
| 003 | DE-627 | ||
| 005 | 20231226075056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/028.2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358591236 | ||
| 035 | |a (NLM)37357766 | ||
| 035 | |a (PII)roig27jun2023 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pérez Catalán, I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nirmatrelvir/ritonavir as a possible treatment for Long-COVID |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Post-Acute COVID-19 Syndrome | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a combination | |
| 650 | 4 | |a nirmaltrevir | |
| 650 | 4 | |a ritonavir | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Gascón Buj, A |e verfasserin |4 aut | |
| 700 | 1 | |a García Muñoz, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Alfaro, I |e verfasserin |4 aut | |
| 700 | 1 | |a Roig Martí, C |e verfasserin |4 aut | |
| 700 | 1 | |a Torres García, M |e verfasserin |4 aut | |
| 700 | 1 | |a Reig Valero, R |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrando Piqueres, R |e verfasserin |4 aut | |
| 700 | 1 | |a Mateu Campos, L |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Rincón, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Usó Blasco, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 36(2023), 5 vom: 03. Okt., Seite 545-546 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:5 |g day:03 |g month:10 |g pages:545-546 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/028.2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 5 |b 03 |c 10 |h 545-546 | ||